Orlov S. Nicole Schaeffer Sells 91,140 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the transaction, the insider now owns 97,083 shares in the company, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Insmed Price Performance

NASDAQ INSM opened at $76.58 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.63. The company has a market cap of $13.70 billion, a PE ratio of -13.80 and a beta of 1.12. The stock’s 50-day moving average price is $72.40 and its two-hundred day moving average price is $72.98.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. During the same quarter in the prior year, the company earned ($1.10) EPS. Insmed’s revenue for the quarter was up 18.1% compared to the same quarter last year. On average, analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on INSM. Truist Financial reissued a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Bank of America increased their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Institutional Trading of Insmed

Several large investors have recently added to or reduced their stakes in INSM. CIBC Asset Management Inc grew its holdings in shares of Insmed by 3.5% during the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 149 shares in the last quarter. Abel Hall LLC boosted its position in Insmed by 4.7% during the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 151 shares during the period. Commerce Bank grew its stake in Insmed by 2.4% during the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 163 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 183 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Insmed by 3.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock worth $446,000 after purchasing an additional 186 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.